Meridian Bioscience

Meridian Bioscience Revenue per Employee

The Revenue per Employee of Meridian Bioscience (VIVO) as of Oct 27, 2026 is 504,572.73 USD. In the previous year, Revenue per Employee was 481,660.61 USD — a change of 4.76% (higher).

Revenue per Employee

504,572.73USD

YoY

4.76%

Last updated:

Revenue per Employee of Meridian Bioscience is 2022 504,572.73 USD. Revenue per Employee of Meridian Bioscience was 2021 481,660.61 USD. It decreases by 4.76% higher compared to the previous year.

The Meridian Bioscience Revenue per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Employee
Date
Revenue per Employee
Jan 1, 2015
295,151.52 USD
Jan 1, 2016
297,121.21 USD
Jan 1, 2017
304,242.42 USD
Jan 1, 2018
323,636.36 USD
Jan 1, 2019
304,545.45 USD
Jan 1, 2020
384,393.94 USD
Jan 1, 2021
481,660.61 USD
Jan 1, 2022
504,572.73 USD
The Meridian Bioscience Revenue per Employee history
YEARRevenue per EmployeeYoY
504,572.73USD+4.76%
481,660.61USD+25.30%
384,393.94USD+26.22%
304,545.45USD-5.90%
323,636.36USD+6.37%
304,242.42USD+2.40%
297,121.21USD+0.67%
295,151.52USD+3.18%
286,060.61USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Meridian Bioscience Stock analysis

What does Meridian Bioscience do? Meridian Bioscience Inc. is a global company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. The company was founded in 1976 by William J. Motto and initially focused on the development of enzyme immunoassays (EIA). Over the years, the company has grown and diversified its product offerings, becoming a leading provider of diagnostic test kits for acute and chronic medical conditions, infectious diseases, gastrointestinal infections, and virology. The company's success is attributed to its diverse range of test kits in various medical areas, including immunology, infectious diseases, sexually transmitted diseases, gastroenterology, and virology. Additionally, Meridian Bioscience Inc. stays up-to-date with the latest technological advancements in biotechnology to ensure the fast and effective performance of its tests. The company operates globally, collaborating with universities, research institutions, government agencies, and distributors to ensure the worldwide distribution and marketing of its products. In summary, Meridian Bioscience Inc. is an innovative company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. Its wide range of products, including immunology products, infectious disease diagnostics, sexually transmitted disease test kits, gastroenterology, virology, and molecular diagnostics, coupled with advanced technologies, provides fast, accurate, and reliable diagnostic support. Meridian Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Meridian Bioscience stock

Revenue per Employee of Meridian Bioscience is 504,572.73 USD in 2022.

Revenue per Employee of Meridian Bioscience changed from 481,660.61 USD to 504,572.73 USD, representing a 4.76% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Revenue per Employee Meridian Bioscience since 2006 – with annual values, charts, and detailed analysis.

Revenue per employee measures workforce productivity by dividing total revenue by the number of employees. Higher values indicate more efficient operations.

Revenue per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Revenue per Employee's Meridian Bioscience historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Meridian Bioscience

All Key Metrics — Meridian Bioscience